不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
P3-GemOx 作为 NK/T 细胞淋巴瘤管理中的新型免疫化疗候选方案
英文原题：P3-GemOx as a novel immunochemotherapy candidate in NK/T-cell lymphoma management.
查看英文原题
P3-GemOx as a novel immunochemotherapy candidate in NK/T-cell lymphoma management.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
P3-GemOx 方案在晚期 NKTL 中显示出优于 PP-GemOx 方案的疗效。
研究思路结论见上方概要
背景
自然杀伤/T细胞淋巴瘤（NKTL）是一种罕见疾病，对现有疗法的反应欠佳。本研究报道了P3-GemOx方案与传统PP-GemOx方案在晚期NKTL中的疗效比较。
方法
11例患者接受了P3-GemOx方案[盐酸米托蒽醌脂质体(Plm60)联合PP-GemOx(抗PD-1抗体、培门冬酶、吉西他滨和奥沙利铂)]，每3-4周一次，中位周期数为3个周期(范围：1-4)。另外11例患者接受了PP-GemOx方案，每3-4周一次，中位周期数为4个周期(范围：2-6)。采用18F-FDG-PET联合CT或MRI评估治疗反应。
结果
所有接受P3-GemOx治疗的患者均有应答，其中9例达到完全缓解（CR），2例达到部分缓解（PR），总体缓解率（ORR）为100%。这些患者中有7例接受了造血干细胞移植（HSCT）。在PP-GemOx组中，ORR为63.6%，且无患者接受HSCT。所有不良事件均可管理并得到缓解。
展开英文摘要原文
METHODS
Eleven patients received the P3-GemOx regimen [mitoxantrone hydrochloride liposome (Plm60) combined with PP-GemOx (anti-PD-1 antibody, pegaspargase, gemcitabine, and oxaliplatin)] every 3-4 weeks, with a median of 3 cycles (range: 1-4). Another eleven patients received the PP-GemOx regimen every 3-4 weeks, with a median of 4 cycles (range: 2-6). Treatment response was assessed using 18F-FDG-PET with CT or MRI.
RESULTS
All patients treated with P3-GemOx responded, with nine achieving complete remission (CR) and two partial remission (PR), yielding an overall response rate (ORR) of 100%. Seven of these patients underwent hematopoietic stem cell transplantation (HSCT). In the PP-GemOx group, the ORR was 63.6%, and no patients underwent HSCT. All adverse events were manageable and resolved. DISCUSSION: The P3-GemOx regimen demonstrates superior efficacy over the PP-GemOx regimen in advanced NKTL.
论文信息
- 作者
- Zhang Y、Kou H、Cheng Z、Lu X、Hu Y、Tang LV
- 单位
- Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Dadao, Wuhan, China.China
- 期刊
- Frontiers in medicine2025
- 原文标识
- PubMed 41210879 · DOI 10.3389/fmed.2025.1666601
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →